Dezandrodeg clinical trials
Also written BMS-986365 and CC-94676.
How each study uses dezandrodeg is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Often tested with
Tested in the same studies.
Gridegalutamide (1) · Androgen Receptor Degrader CC1083610 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test dezandrodeg, phase 3 first.
Studies
Open first, then newest update. How each study uses dezandrodeg is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 3CelgeneNCT06764485Written as BMS-986365
- A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male ParticipantsTerminatedPhase 1CelgeneNCT07242781Written as BMS-986365
- Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedPhase 1CelgeneNCT04428788Written as CC-94676
- A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male ParticipantsCompletedPhase 1CelgeneNCT06433505Written as BMS-986365
- Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male ParticipantsCompletedPhase 1CelgeneNCT06417229Written as BMS-986365
Codes
What other systems call dezandrodeg · ClinicalTrials.gg INT016040
- UNII (FDA) AX6MG4H2RTDEZANDRODEGOne source FDA
- NCI Thesaurus C226271DezandrodegOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | AX6MG4H2RT | DEZANDRODEG | One source FDA |
| NCI Thesaurus | C226271 | Dezandrodeg | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.